+7%
organic growth
Investing in Coloplast
A Medtech leader, positioned for long-term value creation
We have a track record of solid financial performance, driven by innovation and market leadership. Our operational excellence, combined with organic and inorganic investments in new technologies, position us well to deliver long-term value creation through above-market organic growth and industry-leading profitability. Positioned for long-term value creation through investments in new technologies, both organically and inorganically, and operational excellence.
Our key figures (data from FY 2024/25)
28%
EBIT margin (before special items)
27.9 bn
dkk revenue
15%
ROIC after tax
*Before special items and adjusted for impact from Kerecis IP transfer
*Before special items and adjusted for impact from Kerecis IP transfer
Making life easier for people with intimate healthcare needs
Coloplast develops products and services that make life easier for people with intimate healthcare needs.
Founded in Denmark, we’re now a global business, with about 16,500 employees in more than 40 countries. We operate in five areas: Ostomy Care, Continence Care, Voice and Respiratory Care, Advanced Wound Care and Interventional Urology. The combined market is worth an estimated DKK 110-120 billion, with an estimated yearly growth of 4-5%, driven by trends of ageing demographics and expanding healthcare coverage in emerging markets.
The company’s long-term financial goal is to deliver organic growth of 8–10% and an EBIT margin of above 30%.
Through our innovative products and differentiated technologies, we continue to grow our business, while helping people take control of their health.
2 million+
people helped by our products
140
countries in which our products are sold
Sophie
|
User, Ostomy Care
Why invest in Coloplast
Market leader in Chronic Care
We hold the global #1 position in Chronic Care (Ostomy and Continence Care). Building on this strong foundation, we see significant market expansion opportunities outside Europe. Our strategy for driving continued above-market growth is focused on the underpenetrated US market and fast-growing emerging markets.
Growth opportunities outside of Chronic Care
Looking beyond the Chronic Care market, we’ve invested in important growth platforms through M&A.
We see many growth opportunities in the segments we’ve now entered, including the ‘white space’ (unserved patients) in Voice and Respiratory Care, the underpenetrated biologics market in Advanced Wound Care, and fast-growing adjacencies in Interventional Urology, such as the over-active bladder segment.
A culture of innovation
At its core, Coloplast has a strong culture of innovation and customer focus, dedicated to improving patient outcomes through products and services.
Through innovation, we aim to benefit users, while at the same time creating value for healthcare professionals, payers and the society.
Operational excellence
We’re driving operational efficiency and scalable infrastructure through a robust manufacturing setup, our business support centre in Poland, and our streamlined IT infrastructure.
By optimising our manufacturing footprint, investing in automation and improving productivity, we’re reducing costs and benefiting from scalability and simplicity.
Financial strength
We have a strong track record of earnings growth, cash flow generation, and a solid return on invested capital, based on growth above the market and operational efficiency.
Predictable returns
We have a unique mix of high growth and stable and predictable dividend payout. Excess liquidity is returned to shareholders, with a targeted payout ratio of 60–80% of the Group’s net profit.
Purpose-driven organisation
We’re a purpose-driven global organisation, with a unique culture rooted in Denmark. The company is led by an experienced management team with a strong track record.
Our commitment to making life easier for people with intimate healthcare needs sits at the core of our success.